Fundraising FoxThird Rock Ventures — 2015 Investments
12 investments dated 2015 · listed companies and verified rows first · show all
A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.
BiotechArlington, US
Justin Hanes(Director)inKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)inTodd Bazemore(Executive Officer)inMark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in
Board seatRobert Tepper· per SEC Form D
Co-investorsLongitude CapitalSR One Capital ManagementWellington ManagementYsios CapitalAtlas VentureLux Capital+1 more
Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases of the central nervous system, including Alzheimer's disease, ALS, and Parkinson's disease.
BiotechHealthtechLexington, US
Todd Carter(Executive Officer)inRobin Swartz(Executive Officer)inAlfred Sandrock(Executive Officer, Director)Peter Pfreundschuh(Executive Officer)inNathan Jorgensen(Chief Financial Officer; Principal Financial Officer and Principal Accounting Officer)Steven Hyman(Director)
Board seatMark Levin· per SEC Form D
Co-investorsWellington ManagementARCH Venture PartnersFidelity Investments
Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.
BiotechDeep TechMedical DevicesCambridge, US
Feng Zhang(Founder)inGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKatrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)in
Co-investorsEcoR1 CapitalGV (Google Ventures)Sofinnova VenturesViking GlobalAtlas VentureDeerfield Management Company+2 more
BiotechSan Mateo, US
Anthony Ford(Executive Officer)inMichael Kitt(Executive Officer)inKathleen Sereda Glaub(Executive Officer, Director)in
BoardArthur Pappas(Director)Liam Ratcliffe(Director)
Board seatKevin Starr· per SEC Form D
Co-investorsPappas CapitalDomain AssociatesFidelity InvestmentsJennison Associates
Developing therapeutics targeting epigenetic regulators to modulate gene expression; acquired by MorphoSys in June 2021 for $1.7B.
BiotechHealthtechCambridge, US
Michael R. Cooper(Executive Officer)inJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)inTom Maniatis(Director)
Board seatRobert Tepper· per SEC Form D
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesThe Column GroupVenrock
Jounce Therapeutics was a Cambridge, MA clinical-stage biopharmaceutical company developing cancer immunotherapies, including antibodies targeting ICOS and LILRB2/ILT4, guided by a biomarker-driven discovery platform.
BiotechCambridge, US
Kim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)inRichard Murray(Executive Officer, Director)
Board seatRobert KamenCary PfefferRobert Tepper· per SEC Form D
Co-investorsBoutique Venture PartnersGENERAL INCEPTIONNextech InvestSofinnova VenturesVenture Capital Investment ManagementWellington Management
HealthtechBedford, US
Christopher von Jako(Executive Officer, Director)inJudith M. Huber(Executive Officer)inCharles Carignan(Executive Officer, Director)Eric Swanson(Director)
BoardRussell Hirsch(Director)
Board seatMark Levin· per SEC Form D
Co-investorsProspect Venture Partners
Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.
BiotechDigital HealthHealthtechMedical DevicesBoston, US
Keith Gottesdiener(Executive Officer, Director)inBart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDavid Meeker(President and Chief Executive Officer)in
BoardEdward T. Mathers(Director)inJonathan Silverstein(Director)in
Board seatNeil Exter· per SEC Form D · $40M raise · filed Dec 2015
Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)Pfizer Venture InvestmentsWellington ManagementOrbiMed
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Allena PharmaceuticalsDecibel TherapeuticsLyceraMyokardia
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.